FCGR3A and breast cancer: We did not find appreciable numbers of CD56+ or CD16+ NK subsets in our patient’s primary breast cancer (LBC, pT2 pN2a Mo), with immunohistochemistry (IHC) compatible with “Luminal A subtype” (data not shown because IHC for CD56 and CD16 was essentially negative in the primary tumor).